New Bemotrizinol Sunscreen Boost: FDA Calls for Comments
Published Date: 12/12/2025
Notice
Summary
The FDA is proposing a change to sunscreen rules to allow a new ingredient called bemotrizinol at up to 6% in over-the-counter sunscreens. This means sunscreen makers can use this ingredient once the rule is final, helping improve sun protection options. People and companies should send their thoughts by January 26, 2026, so the FDA can decide soon.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
GRASE Status for Bemotrizinol Products
If finalized, the proposed order would find that sunscreen drug products containing bemotrizinol are generally recognized as safe and effective (GRASE) when they meet the conditions set out in OTC Monograph M020. That determination would allow manufacturers to market bemotrizinol-containing OTC sunscreens under the monograph framework.
Bemotrizinol Allowed up to 6%
The FDA proposes adding bemotrizinol as an over-the-counter sunscreen active ingredient at concentrations up to 6 percent in OTC Monograph M020 if the proposed order (OTC000039) is finalized. This change would allow sunscreen products with bemotrizinol to be marketed under the OTC monograph conditions described in M020.
Permitted Dosage Forms and Spray Limits
The proposed order would permit bemotrizinol in specified dosage forms: oil, lotion, cream, gel, butter, paste, ointment, stick, and spray. Spray forms are allowed only if manufactured and packaged with no propellant or if any propellant is isolated from the drug formulation so there is no contact between propellant and the product formulation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-22648 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; Title-National Incident-Based Reporting System (NIBRS)
The FBI wants to keep collecting crime data through the National Incident-Based Reporting System (NIBRS) and is asking for public feedback for 60 days until February 10, 2026. This helps law enforcement track crime better without adding extra paperwork stress. If you’re involved in crime reporting, your input can help make the process smoother and more useful!
Next: 2025-22650 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extension: Rule 17f-7
The SEC wants to keep the rules that help investment funds safely store their foreign assets with trusted banks. Funds and their advisers must get risk reports and have contracts ensuring ongoing risk checks. This update keeps protections strong without adding new costs or deadlines.